Anixa Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANIX Nasdaq 2836 www.anixa.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Anixa Biosciences, Inc.

Anixa Biosciences Leads 3 Promising Penny Stocks On US Exchanges - Jan 17th, 2025 1:07 pm
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans - Jan 14th, 2025 10:07 am
iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024 - Dec 6th, 2024 1:30 pm
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 - Dec 4th, 2024 1:30 pm
Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Could Be 20% Below Their Intrinsic Value Estimate - Dec 4th, 2024 11:17 am
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial - Nov 18th, 2024 1:20 pm
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - Nov 8th, 2024 6:17 pm
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - Nov 6th, 2024 1:30 pm
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 - Oct 31st, 2024 12:15 pm
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - Oct 28th, 2024 12:30 pm
US Penny Stocks To Consider In October 2024 - Oct 24th, 2024 8:06 pm
Anixa Biosciences administers second CAR-T dose in ovarian cancer trial - Oct 16th, 2024 9:42 am
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial - Oct 15th, 2024 1:00 pm
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development - Oct 7th, 2024 12:30 pm
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial - Sep 30th, 2024 12:30 pm
Anixa announces plans to launch Phase II breast cancer vaccine trial - Sep 25th, 2024 8:52 am
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine - Sep 24th, 2024 12:30 pm
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference - Sep 18th, 2024 12:30 pm
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium - Sep 3rd, 2024 12:30 pm
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Aug 26th, 2024 12:30 pm